IGI Logo

Business Overview:

JSLL, headquartered in Zirakpur, Punjab, is a leading provider of Ayurvedic healthcare services and products, focussed on delivering affordable, high-quality and holistic treatment. The company has built a strong pan-India presence with a strong network of 61 hospitals and 58 clinics and day-care centres with 330+ Ayurvedic medicines & wellness products. Its primary healthcare facilities function under the name Shuddhi Ayurveda Panchakarma Hospital (HIIMS), focusing on the treatment of various health conditions including cancer, diabetes, liver disorders, arthritis, high cholesterol, thyroid issues.

Can JSLL’s aggressive bed expansion strategy unlock sustained long-term growth?

JSLL currently operates around 2,861 beds, of which nearly 2,300 are functional, and aims to expand its capacity to 7,000–10,000 beds over the next 3–5 years, representing a 2.5–3.5x increase. With a relatively low capex requirement of INR 3–4 lakh per bed and targeted occupancy levels of 70–80%, the expansion is expected to drive higher patient volumes, improve operating leverage, and enhance profitability. Furthermore, nearly 450 beds have already been constructed but are yet to become operational, offering immediate growth potential without additional capital investment and improving long-term earnings visibility.

Can OTC product expansion significantly reshape JSLL’s revenue profile?

JSLL’s OTC business is emerging as one of its most scalable and promising growth segments. Its flagship Pet Yakrit Pleeha Shuddhi Kit has crossed INR 100 Mn in monthly sales, reflecting strong consumer acceptance and demand. The company currently markets nine OTC products, most introduced within the last few months, while several additional launches are in the pipeline. Management remains confident of scaling OTC revenues to nearly INR 5,000 Mn over the next two years, which could materially alter the company’s revenue mix and growth trajectory.

Can JSLL maintain its industry-leading margins while scaling operations rapidly?

JSLL delivered a robust EBITDA margin of 44% and PAT margin of 28% despite actively investing in expansion, highlighting strong operational efficiency and cost discipline. Its low-cost bed addition strategy, requiring only INR 3–4 lakh per bed, coupled with plans to increase occupancy toward 70–80%, should further improve fixed-cost absorption. Moreover, a growing contribution from high-margin OTC products and increased patient inflows through insurance partnerships are likely to support profitability

Can international expansion strengthen JSLL’s earnings potential and global positioning?

JSLL has already established two international day-care centres in Abu Dhabi and is in the process of launching four additional facilities in Dubai, while also expanding into Nepal and Kazakhstan and evaluating entry into the US market. Supported by insurance-backed treatments and a premium wellness proposition, the international expansion strategy has the potential to diversify revenues, improve margins, and create a scalable platform for long-term earnings growth.

Why invest in JSLL?

Driven by strong financial growth, scalable capacity expansion and high-margin diversification, JSLL presents a compelling investment opportunity. The bed capacity is set to expand 2.5–3.5× to 7,000–10,000 beds over 3–5 years. The OTC segment targets INR 500Cr revenue within two years, enhancing margin profile. Additionally, international expansion and operating leverage support management’s vision to scale profits from ~INR 225 Cr to INR 1,000 Cr, providing strong long-term earnings visibility and return potential

Recommendation: We currently have a ‘BUY’ rating on the stock with a target price of INR 1,000.

Key Risks:

* Key-man risk: As the founder and driving force behind JSLL, Mr. Manish Grover is deeply involved in operations, strategy, brand and vision. Any disruption to his leadership could impact decision-making, culture or stakeholder trust

* Consumer complaints: JSLL may face consumer complaints and lawsuits over defective products or treatment-related injuries, damaging reputation and confidence

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131